Plant-Derived Antioxidants and Their Therapeutic Applications: Molecular Mechanisms, Bioavailability Challenges, and Translational Potential in Disease Prevention and Management

Dr. Arvind Kumar Singh [1*], Dr. Meera Lakshmi [2], Dr. Rahul Prakash Sharma
[1] Centre for Advanced Drug Delivery Systems, Indian Institute of Technology Bombay, Mumbai, India
[2] Institute of Nano Science and Technology, Mohali, India
[3] Department of Pharmaceutics and Nanotechnology, National Institute of Pharmaceutical Education and Research (NIPER), Mohali, India

* Corresponding Author: **Dr. CH Kantlam**

Article Info

ISSN (online): 3107-393X
Volume: 01
Issue: 01
January – February 2024
Received: 15-11-2023
Accepted: 17-12-2023
Published: 19-01-2024
Page No: 48-56

Abstract
Plant-derived antioxidants represent a diverse array of bioactive compounds with significant therapeutic potential across multiple disease states. This review critically examines the molecular mechanisms underlying antioxidant activity, including free-radical scavenging, metal chelation, and modulation of cellular redox signaling pathways. We evaluate the translational applications of polyphenols, flavonoids, carotenoids, and related phytochemicals in cancer prevention, cardiovascular disease, neurodegeneration, and metabolic disorders. Despite promising preclinical evidence, clinical translation faces substantial challenges related to bioavailability, metabolic stability, and pharmacokinetic variability. Emerging formulation strategies, including nanoencapsulation and structural modification, offer promising solutions to enhance therapeutic efficacy. This comprehensive analysis highlights the current state of knowledge, identifies critical gaps in translational research, and proposes future directions for developing plant-derived antioxidants as evidence-based therapeutic agents.

DOI:

Keywords: Plant antioxidants, oxidative stress, polyphenols, flavonoids, bioavailability, therapeutic applications, molecular mechanisms

1. Introduction

Oxidative stress, characterized by an imbalance between reactive oxygen species (ROS) production and antioxidant defense mechanisms, constitutes a fundamental pathophysiological process underlying numerous chronic diseases [1, 2]. Excessive ROS generation promotes cellular damage through lipid peroxidation, protein oxidation, and DNA modifications, contributing to carcinogenesis, atherosclerosis, neurodegeneration, and metabolic dysfunction [2, 4]. While endogenous antioxidant systems provide primary defense mechanisms, their capacity becomes overwhelmed under pathological conditions, necessitating therapeutic intervention [5].

Plant-derived antioxidants have emerged as promising candidates for disease prevention and management due to their chemical diversity, multi-target activity, and generally favorable safety profiles [6, 7]. These compounds encompass structurally diverse classes including polyphenols, flavonoids, carotenoids, phenolic acids, alkaloids, and terpenoids, each exhibiting distinct mechanisms of antioxidant activity [8]. Unlike synthetic antioxidants, phytochemical antioxidants often demonstrate pleiotropic effects, modulating multiple cellular pathways beyond simple ROS scavenging [9, 10].

The therapeutic potential of plant-derived antioxidants has been extensively investigated in preclinical models, demonstrating

efficacy in cancer chemoprevention, cardiovascular protection, neuroprotection, and metabolic regulation [11, 12]. However, translation to clinical applications faces significant challenges related to bioavailability, metabolic stability, tissue distribution, and standardization [13, 14]. Understanding the molecular mechanisms, pharmacokinetic properties, and formulation strategies is essential for developing evidence-based therapeutic interventions.

This review aims to provide a comprehensive analysis of plant-derived antioxidants, focusing on their classification, molecular mechanisms, therapeutic applications, bioavailability challenges, and translational potential. By examining current evidence and identifying research gaps, we propose strategic directions for advancing these compounds toward clinical implementation.

2. Classification of Plant-Derived Antioxidants

2.1. Polyphenols and Flavonoids

Polyphenols represent the most abundant and structurally diverse class of plant antioxidants, characterized by multiple phenolic hydroxyl groups attached to aromatic ring structures [15]. This class encompasses several subgroups with distinct structural features and biological activities (Figure 1, Table 1).

Flavonoids constitute the largest polyphenolic subclass, comprising over 6,000 identified compounds organized into six major categories: flavonols (quercetin, kaempferol), flavones (apigenin, luteolin), flavanones (naringenin, hesperetin), flavan-3-ols (catechins, epicatechins), anthocyanins (cyanidin, delphinidin), and isoflavones (genistein, daidzein) [16, 17]. These compounds exhibit variable antioxidant potency depending on hydroxyl group positioning, glycosylation patterns, and structural modifications [18].

Phenolic acids, including hydroxybenzoic acids (gallic acid, protocatechuic acid) and hydroxycinnamic acids (caffeic acid, ferulic acid, chlorogenic acid), demonstrate potent radical-scavenging activity and metal-chelating properties [19]. Stilbenes, exemplified by resveratrol and pterostilbene, possess unique trans-configured double bonds connecting two phenolic rings, conferring distinctive biological activities [20].

2.2. Carotenoids

Carotenoids comprise lipophilic tetraterpenoid pigments responsible for yellow, orange, and red coloration in plants [21]. Structurally, these compounds contain extended conjugated double-bond systems that enable efficient quenching of singlet oxygen and free-radical scavenging [22]. Major categories include carotenes (β-carotene, lycopene, α-carotene) and xanthophylls (lutein, zeaxanthin, β-cryptoxanthin) [23].

β-carotene serves as a provitamin A precursor while demonstrating independent antioxidant activity through radical-addition reactions and energy transfer mechanisms [24]. Lycopene, lacking provitamin A activity, exhibits superior singlet oxygen quenching capacity attributed to its highly conjugated structure [25]. Xanthophylls contain oxygen functional groups that enhance polarity and enable specific tissue accumulation, particularly in ocular tissues [26].

2.3. Other Bioactive Antioxidant Phytochemicals

Alkaloids, nitrogen-containing plant metabolites, exhibit antioxidant properties through multiple mechanisms. Berberine, palmatine, and sanguinarine demonstrate ROS-scavenging activity alongside modulation of antioxidant enzyme expression [27]. Terpenoids, including monoterpenes, sesquiterpenes, and diterpenes, contribute antioxidant activity through hydrogen donation and radical stabilization [28]. Organosulfur compounds from Allium species, such as allicin and diallyl disulfide, provide antioxidant protection through direct radical scavenging and upregulation of cellular defense systems [29].

3. Molecular Mechanisms of Antioxidant Action

3.1. Free-Radical Scavenging

Plant-derived antioxidants neutralize free radicals through hydrogen-atom transfer (HAT) and single-electron transfer (SET) mechanisms (Figure 2, Table 2) [20]. The efficiency of radical scavenging depends on structural features including phenolic hydroxyl groups, conjugated double bonds, and electron-donating substituents [21]. Polyphenolic compounds donate hydrogen atoms from hydroxyl groups to radicals, forming stable phenoxyl radicals stabilized through resonance delocalization [22].

The ortho-dihydroxy (catechol) structure in flavonoids significantly enhances antioxidant capacity by enabling electron delocalization and forming stable quinone structures [23]. The C2-C3 double bond in the C-ring conjugated with the 4-oxo function and the presence of additional hydroxyl groups at positions 3, 5, and 7 further augment radical-scavenging efficiency [24].

Carotenoids scavenge peroxyl radicals through radical-addition reactions, where the radical attacks the conjugated polyene chain, forming carbon-centered radical adducts that subsequently stabilize through resonance [25]. This mechanism effectively terminates lipid peroxidation chain reactions, preventing membrane damage [26].

3.2. Metal Chelation

Transition metal chelation represents a crucial antioxidant mechanism, preventing metal-catalyzed ROS generation through Fenton and Haber-Weiss reactions [27]. Polyphenols chelate iron and copper ions through catechol moieties, forming stable metal-polyphenol complexes that inhibit metal-mediated oxidative damage [28]. The catechol structure in the B-ring, combined with the 3-hydroxy and 4-oxo groups in the C-ring, creates optimal metal-binding sites in flavonoids [29].

3.3. Modulation of Cellular Redox Signaling

Beyond direct radical scavenging, plant antioxidants modulate intracellular redox signaling pathways (Figure 3) [40]. Nuclear factor erythroid 2-related factor 2 (Nrf2) activation constitutes a primary mechanism whereby phytochemical antioxidants induce cytoprotective gene expression [41]. Polyphenols promote Nrf2 nuclear translocation by disrupting Keap1-Nrf2 interaction, leading to upregulation of phase II detoxification enzymes and antioxidant proteins including heme oxygenase-1, NAD(P)H quinone oxidoreductase 1, and glutathione S-transferases [42, 43].

Plant antioxidants also modulate mitogen-activated protein kinase (MAPK) signaling, influencing cellular responses to oxidative stress [44]. Selective inhibition of pro-oxidant signaling cascades, including JNK and p38 MAPK, reduces oxidative stress-induced apoptosis while preserving essential cellular functions [45].

3.4. Anti-inflammatory and Cytoprotective Pathways

Plant-derived antioxidants suppress inflammatory responses by inhibiting nuclear factor-kappa B (NF-κB) activation, thereby reducing expression of pro-inflammatory cytokines, cyclooxygenase-2, and inducible nitric oxide synthase [46, 47]. These compounds also modulate inflammasome activation, particularly NLRP3, attenuating sterile inflammation associated with oxidative stress [48]. Additionally, plant antioxidants activate cellular survival pathways including PI3K/Akt and AMPK, promoting cellular adaptation to oxidative challenges [49, 50].

4. Therapeutic Applications

4.1. Cancer Prevention and Adjunct Therapy

Plant-derived antioxidants demonstrate significant cancer chemopreventive potential through multiple mechanisms (Table 3) [51]. These compounds inhibit carcinogen activation, enhance detoxification, induce apoptosis in transformed cells, and suppress angiogenesis and metastasis [52, 53]. Epigallocatechin gallate from green tea inhibits tumor cell proliferation through modulation of epidermal growth factor receptor signaling and induction of cell-cycle arrest [54]. Curcumin demonstrates anti-cancer activity by suppressing NF-κB-mediated survival signaling and inducing mitochondrial apoptotic pathways [55].

Resveratrol exhibits chemopreventive effects by activating SIRT1-mediated cellular stress responses and inhibiting cyclooxygenase-2 expression [56]. Lycopene reduces prostate cancer risk through inhibition of insulin-like growth factor signaling and modulation of androgen receptor activity [57]. Clinical studies demonstrate that polyphenol-rich interventions reduce biomarkers of oxidative DNA damage and improve immune surveillance in high-risk populations [58].

4.2. Cardiovascular and Metabolic Disorders

Plant antioxidants provide cardiovascular protection through multiple complementary mechanisms [59]. Flavonoids improve endothelial function by enhancing nitric oxide bioavailability, reducing oxidative modification of low-density lipoproteins, and inhibiting platelet aggregation [60]. Anthocyanins reduce blood pressure through endothelium-dependent vasodilation and improvement of arterial stiffness. In metabolic disorders, plant antioxidants improve insulin sensitivity, reduce hepatic steatosis, and ameliorate diabetic complications. Quercetin enhances glucose uptake in skeletal muscle through AMPK activation and GLUT4 translocation. Berberine demonstrates anti-diabetic effects by modulating gut microbiota composition and improving intestinal barrier function. Clinical trials confirm that flavonoid supplementation reduces cardiovascular risk factors including blood pressure, lipid profiles, and inflammatory markers.

4.3. Neurodegenerative and Inflammatory Diseases

Neuroprotective effects of plant antioxidants address multiple pathological features of neurodegenerative diseases. These compounds cross the blood-brain barrier, accumulate in neural tissues, and mitigate oxidative damage, neuroinflammation, and protein aggregation. Flavonoids enhance cognitive function through modulation of synaptic plasticity, neurogenesis, and cerebral blood flow.

Epigallocatechin gallate inhibits amyloid-β aggregation and tau hyperphosphorylation in Alzheimer's disease models. Curcumin demonstrates neuroprotective effects by activating brain-derived neurotrophic factor signaling and reducing α-synuclein aggregation in Parkinson's disease. In inflammatory conditions, plant antioxidants suppress pro-inflammatory mediator production and enhance resolution of inflammation.

5. Bioavailability, Stability, and Delivery Challenges

5.1. Absorption, Metabolism, and Pharmacokinetics

Limited bioavailability represents the primary obstacle to therapeutic efficacy of plant-derived antioxidants (Figure 4, Table 4). Most polyphenols exhibit poor intestinal absorption due to hydrophilicity, large molecular size, and extensive conjugation. Following oral administration, these compounds undergo extensive first-pass metabolism, including glucuronidation, sulfation, and methylation, generating metabolites with altered biological activity.

Flavonoid glycosides require enzymatic deglycosylation before absorption, a process dependent on intestinal and colonic microbiota. Aglycone forms demonstrate higher absorption rates but face rapid phase II conjugation in enterocytes and hepatocytes. Plasma concentrations typically remain in nanomolar to low micromolar ranges, substantially below concentrations demonstrating efficacy *in vitro*.

Carotenoids require incorporation into mixed micelles for intestinal absorption, a process dependent on dietary fat content and bile salt availability. Conversion efficiency of provitamin A carotenoids varies considerably among individuals due to genetic polymorphisms in β-carotene 15,15'-monooxygenase. Tissue accumulation patterns differ significantly among carotenoids, with xanthophylls preferentially accumulating in ocular tissues through specific binding proteins.

5.2. Poor Solubility and Chemical Degradation

Lipophilic antioxidants including carotenoids and certain polyphenols demonstrate extremely low aqueous solubility, limiting dissolution and absorption. Many plant antioxidants undergo chemical degradation during processing, storage, and gastrointestinal transit due to pH sensitivity, oxidation, and photodegradation. Anthocyanins are particularly unstable at neutral and alkaline pH, undergoing structural transformation and color loss.

5.3. Strategies to Improve Therapeutic Efficacy

Multiple formulation approaches aim to enhance bioavailability and therapeutic efficacy (Table 5). Nanoencapsulation technologies including liposomes, solid lipid nanoparticles, and polymeric nanoparticles improve solubility, protect against degradation, and facilitate cellular uptake. Nanoemulsions enhance carotenoid bioavailability by increasing surface area and promoting micelle formation.

Structural modifications, including esterification and glycosylation, can improve stability and absorption while maintaining antioxidant activity. Complexation with cyclodextrins enhances water solubility of lipophilic compounds through inclusion complex formation. Co-administration with piperine, a bioavailability enhancer, inhibits glucuronidation and increases plasma concentrations of multiple polyphenols.

Advanced delivery systems including phytosomes, combining polyphenols with phospholipids, demonstrate superior absorption and tissue distribution compared to conventional formulations. Self-emulsifying drug delivery

systems enable spontaneous emulsion formation upon gastrointestinal dilution, enhancing absorption of poorly soluble compounds.

6. Challenges and Future Perspectives

6.1. Standardization and Dose Consistency

Significant compositional variability among plant extracts due to genetic factors, cultivation conditions, harvesting time, and processing methods complicates standardization. Lack of validated biomarkers for biological activity impedes dose optimization and quality control. Establishing pharmacologically relevant doses requires consideration of bioavailability, metabolism, and target tissue concentrations rather than administered amounts.

6.2. Translational Gaps and Clinical Validation

Despite extensive preclinical evidence, clinical translation remains limited by inadequate pharmacokinetic characterization, suboptimal study designs, and heterogeneous patient populations. Many clinical trials employ doses and formulations with poor bioavailability, yielding inconclusive results. Long-term safety profiles require comprehensive evaluation, particularly at pharmacologically active doses.

6.3. Opportunities in Formulation and Delivery Innovation

Emerging technologies offer promising solutions to bioavailability challenges. Targeted delivery systems utilizing specific ligands can enhance tissue accumulation and cellular uptake. Combination approaches employing multiple plant antioxidants may achieve synergistic effects through complementary mechanisms. Integration of pharmacogenomics can identify patient subpopulations most likely to benefit from specific antioxidant interventions.

Precision medicine approaches incorporating biomarker-guided dosing and real-time monitoring of oxidative stress status may optimize therapeutic outcomes. Development of prodrug strategies that enable targeted activation in diseased tissues could improve efficacy while minimizing systemic exposure. Exploration of gut microbiota modulation to enhance metabolite production represents an innovative approach to improving bioactivity.

7. Conclusion

Plant-derived antioxidants represent a diverse class of bioactive compounds with substantial therapeutic potential across multiple disease states. Their multi-target mechanisms, including direct radical scavenging, metal chelation, and modulation of cellular signaling pathways, position them as promising candidates for disease prevention and management. However, translating preclinical promise into clinical reality requires addressing fundamental challenges related to bioavailability, metabolic stability, standardization, and dose optimization.

Advanced formulation technologies, structural optimization, and precision medicine approaches offer viable solutions to overcome these limitations. Future research must prioritize rigorous pharmacokinetic characterization, biomarker-guided clinical trials, and mechanistic understanding of metabolite activity. Integration of multi-omics approaches can identify molecular signatures predicting therapeutic response and enable personalized antioxidant interventions.

The field stands at a critical juncture where accumulated preclinical knowledge must be systematically translated through well-designed clinical investigations. Success requires collaborative efforts among phytochemists, pharmacologists, formulation scientists, and clinicians to develop evidence-based therapeutic applications. With strategic focus on overcoming bioavailability challenges and establishing clinical efficacy, plant-derived antioxidants hold significant promise as safe, effective, and accessible therapeutic agents for preventing and managing oxidative stress-related diseases.

8. Figures



Fig 1: Classification of plant-derived antioxidants



Fig 2: Molecular mechanisms of antioxidant action



Fig 3: Therapeutic pathways and disease targets



Fig 4: Bioavailability limitations and enhancement strategies

9. Tables

Table 1: Major classes of plant-derived antioxidants and natural sources

Class	Subclass	Representative Compounds	Primary Natural Sources	Structural Features
Polyphenols	Flavonols	Quercetin, Kaempferol, Myricetin	Onions, apples, berries, tea	3-hydroxyflavone backbone
	Flavones	Apigenin, Luteolin	Parsley, celery, chamomile	Flavone backbone without 3-hydroxyl
	Flavanones	Naringenin, Hesperetin	Citrus fruits	Saturated C2-C3 bond
	Flavan-3-ols	Catechin, EGCG	Green tea, cocoa, grapes	Lack 4-oxo function
	Anthocyanins	Cyanidin, Delphinidin	Berries, red grapes, purple vegetables	Flavylium cation structure
	Isoflavones	Genistein, Daidzein	Soybeans, legumes	B-ring at C3 position
	Phenolic acids	Gallic acid, Caffeic acid, Ferulic acid	Coffee, whole grains, fruits	Carboxylic acid group
	Stilbenes	Resveratrol, Pterostilbene	Grapes, berries, peanuts	C6-C2-C6 structure
Carotenoids	Carotenes	β-Carotene, Lycopene, α-Carotene	Carrots, tomatoes, sweet potatoes	Hydrocarbon polyenes
	Xanthophylls	Lutein, Zeaxanthin, β-Cryptoxanthin	Leafy greens, corn, egg yolk	Oxygenated carotenoids
Alkaloids	Isoquinoline	Berberine, Palmatine	Goldenseal, barberry	Quaternary nitrogen
Terpenoids	Monoterpenes	Limonene, Menthol	Citrus, mint	C10 skeleton
Organosulfur	Thiosulfinates	Allicin, Diallyl disulfide	Garlic, onions	Sulfur-containing functional groups

Table 2: Molecular mechanisms and cellular targets

Mechanism	Primary Targets	Representative Compounds	Molecular Events	Biological Outcomes
Direct radical scavenging	ROS, RNS ($O_2^{\bullet-}$, $^{\bullet}OH$, $ONOO^-$)	Quercetin, catechins, resveratrol	Hydrogen donation, electron transfer, radical stabilization	Reduced oxidative damage to lipids, proteins, DNA
Metal chelation	Fe^{2+}, Cu^{2+}	Quercetin, EGCG, curcumin	Complex formation with transition metals	Inhibition of Fenton/Haber-Weiss reactions
Nrf2 activation	Keap1-Nrf2-ARE pathway	Sulforaphane, curcumin, resveratrol	Keap1 thiol modification, Nrf2 nuclear translocation	Upregulation of HO-1, NQO1, GST, GCL
NF-κB inhibition	IKK-IκB-NF-κB pathway	Curcumin, EGCG, resveratrol	IKK inhibition, prevention of IκB degradation	Reduced pro-inflammatory cytokine expression
MAPK modulation	JNK, ERK, p38 MAPK	Quercetin, apigenin, catechins	Selective kinase inhibition	Reduced apoptosis, modulated stress responses
AMPK activation	AMPK-mTOR pathway	Berberine, resveratrol, EGCG	AMP/ATP ratio increase, LKB1 activation	Enhanced glucose uptake, mitochondrial biogenesis
Enzyme inhibition	COX-2, iNOS, LOX	Curcumin, resveratrol, quercetin	Active site binding, expression suppression	Reduced inflammation and oxidative stress
Protein aggregation inhibition	Aβ, α-synuclein, tau	EGCG, curcumin, resveratrol	Interference with fibril formation	Neuroprotection

Table 3: Therapeutic applications across disease categories

Disease Category	Specific Conditions	Key Mechanisms	Effective Compounds	Evidence Level	Clinical Status
Cancer	Colorectal, prostate, breast, lung	Apoptosis induction, angiogenesis inhibition, epigenetic modulation	Curcumin, EGCG, resveratrol, lycopene	Preclinical: Strong; Clinical: Moderate	Phase II/III trials ongoing
Cardiovascular	Atherosclerosis, hypertension, endothelial dysfunction	LDL oxidation prevention, NO bioavailability, anti-platelet	Quercetin, anthocyanins, resveratrol	Preclinical: Strong; Clinical: Strong	Dietary recommendations established
Neurodegenerative	Alzheimer's, Parkinson's, cognitive decline	Neuroprotection, protein aggregation inhibition, anti-inflammatory	EGCG, curcumin, resveratrol	Preclinical: Strong; Clinical: Limited	Early-phase clinical trials
Metabolic	Type 2 diabetes, NAFLD, metabolic syndrome	Insulin sensitization, lipid metabolism, hepatoprotection	Berberine, quercetin, resveratrol	Preclinical: Strong; Clinical: Moderate	Clinical use in some regions
Inflammatory	Rheumatoid arthritis, IBD, chronic inflammation	NF-κB inhibition, inflammasome suppression	Curcumin, EGCG, quercetin	Preclinical: Strong; Clinical: Moderate	Adjunct therapy investigations
Ocular	AMD, cataracts, retinopathy	Retinal protection, photo-oxidative stress reduction	Lutein, zeaxanthin, anthocyanins	Preclinical: Strong; Clinical: Strong	Nutritional supplements available

Table 4: Bioavailability challenges and formulation strategies

Challenge	Mechanism	Affected Compounds	Consequences	Enhancement Strategy	Expected Improvement
Poor aqueous solubility	High lipophilicity, crystalline structure	Curcumin, carotenoids, resveratrol	Limited dissolution, low absorption	Nanoemulsions, solid dispersions, cyclodextrin complexation	5-20 fold increase in Cmax
Extensive metabolism	Phase II conjugation (glucuronidation, sulfation)	Flavonoids, stilbenes, phenolic acids	Low systemic concentrations, rapid clearance	Co-administration with piperine, prodrug design	2-10 fold increase in AUC
Chemical instability	pH sensitivity, oxidation, photodegradation	Anthocyanins, catechins, ascorbic acid	Loss of activity during storage/transit	Nanoencapsulation, coating technologies	Maintained activity >80%
Limited permeability	Large molecular size, hydrophilicity	Glycosylated flavonoids, tannins	Poor membrane transport	Liposomes, phytosomes, nanoparticles	3-8 fold increased absorption
First-pass metabolism	Hepatic and intestinal metabolism	Most polyphenols	Reduced bioavailability	Targeted delivery, structural modification	Bypassing hepatic metabolism
Low tissue accumulation	Rapid elimination, poor distribution	Most water-soluble antioxidants	Insufficient concentrations at target sites	Targeted nanocarriers, PEGylation	5-15 fold increased tissue levels
Individual variability	Genetic polymorphisms, microbiota	Carotenoids, flavonoid glycosides	Inconsistent therapeutic response	Personalized dosing, microbiota modulation	Reduced inter-individual variation

Table 5: Advantages, limitations, and translational considerations

Aspect	Advantages	Limitations	Translational Considerations	Future Directions
Efficacy	Multi-target activity, pleiotropic effects, synergistic combinations	*In vitro-in vivo* discrepancy, low therapeutic concentrations	Biomarker-guided dose optimization, combination therapies	Develop bioavailability-enhanced formulations validated in humans
Safety	Generally low toxicity, long history of dietary consumption	Limited long-term safety data at pharmacological doses	Comprehensive toxicology studies, post-marketing surveillance	Establish therapeutic windows for individual compounds
Bioavailability	Natural packaging in food matrices provides some protection	Poor absorption, extensive metabolism, rapid elimination	Advanced delivery systems, prodrug strategies	Clinical trials using bioavailable formulations
Standardization	Well-characterized chemical structures	Variability in plant sources, lack of pharmacopeial standards	Quality control protocols, marker compound identification	Develop standardized extracts with guaranteed bioactivity
Cost-effectiveness	Abundant natural sources, sustainable production	Expensive extraction and purification processes	Process optimization, biotechnological production	Synthetic biology approaches for key compounds
Regulatory status	GRAS status for many compounds	Unclear regulatory pathway for therapeutic claims	Navigation of dietary supplement vs. drug classification	Establish regulatory frameworks for phytopharmaceuticals
Clinical evidence	Strong preclinical data, epidemiological associations	Limited RCTs, heterogeneous study designs	Rigorous clinical trial design, appropriate endpoints	Large-scale, well-controlled clinical trials
Personalization	Potential for targeted interventions	Unknown response predictors	Pharmacogenomic studies, oxidative stress biomarkers	Precision nutrition and medicine approaches

References

1. Sies H, Jones DP. Reactive oxygen species (ROS) as pleiotropic physiological signalling agents. Nat Rev Mol Cell Biol. 2020;21(7):363–383.
2. Forman HJ, Zhang H. Targeting oxidative stress in disease: promise and limitations of antioxidant therapy. Nat Rev Drug Discov. 2021;20(9):689–709.
3. Pizzino G, Irrera N, Cucinotta M, *et al*. Oxidative stress: harms and benefits for human health. Oxid Med Cell Longev. 2017;2017:8416763.
4. Halliwell B. Understanding mechanisms of antioxidant action in health and disease. Nat Rev Mol Cell Biol. 2024;25(1):13–33.
5. Brieger K, Schiavone S, Miller FJ Jr, Krause KH. Reactive oxygen species: from health to disease. Swiss Med Wkly. 2012;142:w13659.
6. Tungmunnithum D, Thongboonyou A, Pholboon A, Yangsabai A. Flavonoids and other phenolic compounds from medicinal plants for pharmaceutical and medical aspects. Medicines (Basel). 2018;5(3):93.
7. Salehi B, Martorell M, Arbiser JL, *et al*. Antioxidants: positive or negative actors? Biomolecules. 2018;8(4):124.
8. Liu RH. Potential synergy of phytochemicals in cancer prevention: mechanism of action. J Nutr. 2004;134(12 Suppl):3479S–3485S.
9. Sharifi-Rad J, Rayess YE, Rizk AA, *et al*. Turmeric and its major compound curcumin on health: bioactive effects and safety profiles. Front Pharmacol. 2020;11:1021.
10. Panche AN, Diwan AD, Chandra SR. Flavonoids: an overview. J Nutr Sci. 2016;5:e47.
11. Pandey KB, Rizvi SI. Plant polyphenols as dietary antioxidants in human health and disease. Oxid Med Cell Longev. 2009;2(5):270–278.
12. Huang WY, Cai YZ, Zhang Y. Natural phenolic compounds from medicinal herbs and dietary plants. Nutr Cancer. 2010;62(1):1–20.
13. Manach C, Scalbert A, Morand C, Rémésy C, Jiménez L. Polyphenols: food sources and bioavailability. Am J Clin Nutr. 2004;79(5):727–747.
14. D'Archivio M, Filesi C, Varì R, Scazzocchio B, Masella R. Bioavailability of the polyphenols: status and controversies. Int J Mol Sci. 2010;11(4):1321–1342.
15. Tsao R. Chemistry and biochemistry of dietary polyphenols. Nutrients. 2010;2(12):1231–1246.
16. Ullah A, Munir S, Badshah SL, *et al*. Important flavonoids and their role as a therapeutic agent. Molecules. 2020;25(22):5243.
17. Kumar S, Pandey AK. Chemistry and biological activities of flavonoids: an overview. ScientificWorldJournal. 2013;2013:162750.
18. Rice-Evans CA, Miller NJ, Paganga G. Structure–antioxidant activity relationships of flavonoids and phenolic acids. Free Radic Biol Med. 1996;20(7):933–956.
19. Sroka Z, Cisowski W. Hydrogen peroxide scavenging and antioxidant activity of phenolic acids. Food Chem Toxicol. 2003;41(6):753–758.
20. Vervandier-Fasseur D, Latruffe N. The potential use of resveratrol for cancer prevention. Molecules. 2019;24(24):4506.
21. Eggersdorfer M, Wyss A. Carotenoids in human nutrition and health. Arch Biochem Biophys. 2018;652:18–26.
22. Fiedor J, Burda K. Potential role of carotenoids as antioxidants. Nutrients. 2014;6(2):466–488.
23. Maoka T. Carotenoids as natural functional pigments. J Nat Med. 2020;74(1):1–16.
24. Palace VP, Khaper N, Qin Q, Singal PK. Antioxidant potentials of vitamin A and carotenoids. Free Radic Biol Med. 1999;26(5–6):746–761.
25. Di Mascio P, Kaiser S, Sies H. Lycopene as a biological singlet oxygen quencher. Arch Biochem Biophys. 1989;274(2):532–538.
26. Bernstein PS, Li B, Vachali PP, *et al*. Lutein and zeaxanthin in ocular disease. Prog Retin Eye Res. 2016;50:34–66.
27. Neag MA, Mocan A, Echeverría J, *et al*. Berberine: occurrence, uses and relevance. Front Pharmacol. 2018;9:557.
28. Mahajan M, Pal PK, Alghamdi S, *et al*. Structure–antioxidant activity relationship of flavonoids. Food Chem. 2023;420:136076.
29. Santhosha SG, Jamuna P, Prabhavathi SN. Bioactive components of garlic. Food Biosci. 2013;3:59–74.
30. Leopoldini M, Russo N, Toscano M. Molecular mechanisms of polyphenolic antioxidants. Food Chem. 2011;125(2):288–306.
31. Amić D, Davidović-Amić D, Bešlo D, Trinajstić N. Structure–radical scavenging activity relationships of flavonoids. Croat Chem Acta. 2003;76(1):55–61.
32. Pietta PG. Flavonoids as antioxidants. J Nat Prod. 2000;63(7):1035–1042.
33. Heim KE, Tagliaferro AR, Bobilya DJ. Flavonoid antioxidants: chemistry and metabolism. J Nutr Biochem. 2002;13(10):572–584.
34. Burda S, Oleszek W. Antioxidant and antiradical activities of flavonoids. J Agric Food Chem. 2001;49(6):2774–2779.
35. Burton GW, Ingold KU. Beta-carotene: an unusual lipid antioxidant. Science. 1984;224(4649):569–573.
36. Young AJ, Lowe GM. Antioxidant and prooxidant properties of carotenoids. Arch Biochem Biophys. 2001;385(1):20–27.
37. Perron NR, Brumaghim JL. Antioxidant mechanisms of polyphenols related to iron binding. Cell Biochem Biophys. 2009;53(2):75–100.
38. Mira L, Fernandez MT, Santos M, *et al*. Interactions of flavonoids with iron and copper ions. Free Radic Res. 2002;36(11):1199–1208.
39. van Acker SA, van den Berg DJ, Tromp MN, *et al*. Structural aspects of antioxidant activity of flavonoids. Free Radic Biol Med. 1996;20(3):331–342.
40. Hussain T, Tan B, Yin Y, *et al*. Oxidative stress and inflammation: what polyphenols can do. Oxid Med Cell Longev. 2016;2016:7432797.
41. Ma Q. Role of Nrf2 in oxidative stress and toxicity. Annu Rev Pharmacol Toxicol. 2013;53:401–426.
42. Dinkova-Kostova AT, Holtzclaw WD, Cole RN, *et al*. Sulfhydryl groups of Keap1 regulate phase 2 enzyme induction. Proc Natl Acad Sci U S A. 2002;99(18):11908–11913.
43. Zhang DD, Hannink M. Keap1-dependent ubiquitination of Nrf2. Mol Cell Biol. 2003;23(22):8137–8151.

44. Fraga CG, Galleano M, Verstraeten SV, Oteiza PI. Health benefits of polyphenols. Mol Aspects Med. 2010;31(6):435–445.
45. Son Y, Cheong YK, Kim NH, *et al*. ROS-mediated activation of MAPK pathways. J Signal Transduct. 2011;2011:792639.
46. Huang WW, Zhu YY, Wen J, *et al*. Quercetin ameliorates atherosclerosis in ApoE−/− mice. J Nutr Biochem. 2022;102:108940.
47. González R, Ballester I, López-Posadas R, *et al*. Effects of flavonoids on inflammation. Crit Rev Food Sci Nutr. 2011;51(4):331–362.
48. Gao J, Xu K, Liu H, *et al*. Gut microbiota and intestinal immunity. Front Cell Infect Microbiol. 2018;8:13.
49. Spencer JP. Impact of fruit flavonoids on cognition. Br J Nutr. 2010;104(Suppl 3):S40–S47.
50. Baur JA, Sinclair DA. Therapeutic potential of resveratrol. Nat Rev Drug Discov. 2006;5(6):493–506.
51. Russo GL, Spagnuolo C, Russo M, *et al*. Polyphenols and aging. Biochem Pharmacol. 2020;173:113719.
52. Cháirez-Ramírez MH, de la Cruz-López KG, García-Carrancá A. Polyphenols as antitumor agents. Front Pharmacol. 2021;12:710304.
53. Khan H, Reale M, Ullah H, *et al*. Polyphenols targeting p53 signaling. Biotechnol Adv. 2020;38:107385.
54. Yang CS, Wang H, Chen JX, Zhang J. Tea catechins and cancer signaling pathways. Enzymes. 2014;36:195–221.
55. Ravindran J, Prasad S, Aggarwal BB. Curcumin and cancer cells. AAPS J. 2009;11(3):495–510.
56. Jang M, Cai L, Udeani GO, *et al*. Cancer chemopreventive activity of resveratrol. Science. 1997;275(5297):218–220.
57. Holzapfel NP, Holzapfel BM, Champ S, *et al*. Lycopene and prostate cancer. Int J Mol Sci. 2013;14(7):14620–14646.
58. Huang HY, Helzlsouer KJ, Appel LJ. Vitamin C and E effects on oxidative DNA damage. Cancer Epidemiol Biomarkers Prev. 2000;9(7):647–652.
59. Hooper L, Kroon PA, Rimm EB, *et al*. Flavonoids and cardiovascular risk. Am J Clin Nutr. 2008;88(1):38–50.
60. Erlund I. Quercetin, hesperetin, and naringenin: review. Nutr Res. 2004;24(10):851–874.